research use only

Omeprazole Proton Pump inhibitor

Name: Omeprazole
Brand: Selleck Chemicals
SKU: S1389
Availability: InStock
Rating: 5 (10 reviews)

Cat.No.S1389

Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.

Chemical Structure

Molecular Weight: 345.42

Jump to

Quality Control

Batch: Purity: 99.53%

99.53

Related Targets	CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase
Other Proton Pump Products	Bafilomycin A1 (Baf-A1) Ilaprazole sodium Ilaprazole Tenatoprazole Revaprazan Hydrochloride PF-3716556 Ufiprazole

Solubility

In vitro
Batch:

DMSO : 69 mg/mL (199.75 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 13 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	345.42	Formula	C₁₇H₁₉N₃O₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	73590-58-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC

Mechanism of Action

Targets/IC₅₀/Ki	Proton pump H(+)-K(+)-ATPase
In vitro	Omeprazole potently induces cytochrome P4501A1 mRNA expression in primary human hepatocytes, whereas this effect is not detected in mouse primary hepatocytes. This compound induces transcription of reporter genes via the xenobiotic response element that is recognized by the ligand-activated dioxin receptor in human hepatoma cells. It causes a strong inhibition of basal natural killer (NK) activity in spleen cells (SC) from untreated CD2F1 mice. This chemical causes a rapid, strong effect on various types of cytotoxic lymphocytes ranging from cytotoxicity inhibition to irreversible cell damage. It induces a significant inhibition of cytotoxic activity of all types of effector cells after 30 min incubation. This agent decreases the activation of osteoclasts but increases that of osteoblasts in vitro, in part causing an osteopetrosis-like effect.
In vivo	Omeprazole blocks H(+)-K(+)-ATPase, thus enhances degeneration and macrophage-mediated elimination of parietal cells and also causes an increase in preparietal cell production. This compound temporarily changes the dynamic features of parietal cells in the rabbit to make them die early and grow fast.
References	[1] https://pubmed.ncbi.nlm.nih.gov/9139728/ [2] https://pubmed.ncbi.nlm.nih.gov/8795713/ [3] https://pubmed.ncbi.nlm.nih.gov/21042782/ [4] https://pubmed.ncbi.nlm.nih.gov/8179010/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06378398	Not yet recruiting	Colorectal Neoplasia	University of Michigan Rogel Cancer Center\|National Cancer Institute (NCI)	May 2024	Early Phase 1
NCT05671653	Terminated	Obesity	Pfizer	January 19 2023	Phase 1
NCT05635110	Completed	Pain	Vertex Pharmaceuticals Incorporated	December 15 2022	Phase 1
NCT05651074	Recruiting	Healthy Subjects	Jiangsu vcare pharmaceutical technology co. LTD	November 14 2022	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):